List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
A combination of computer simulations and fragment screening have uncovered 27 molecular binding sites on tubulin, a protein of the cell cytoskeleton.
After screening 4,500 compounds using induced pluripotent stem cells, researchers have identified one lead that could treat pulmonary arterial hypertension.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
Researchers have developed their previously created brain organoid to test for potential drugs against Creutzfeldt-Jakob disease (CJD).
Researchers have used fragment screening alongside computational docking to reveal 20 hit antiviral compounds against SARS-CoV-2.
Scientists have shown that culturing cells with a modified serum could allow drugs to be screened for toxicity earlier during research.
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
Dr Sam Liver, Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute, explains how lab automation in the form of machine learning and high‑throughput experimentation (HTE) can be implemented to enhance productivity in autonomous molecular discovery.
